دورية أكاديمية
أعرض في EDS

Temporal patterns of cytokine and injury biomarkers in hospitalized COVID-19 patients treated with methylprednisolone.

التفاصيل البيبلوغرافية
العنوان: Temporal patterns of cytokine and injury biomarkers in hospitalized COVID-19 patients treated with methylprednisolone.
المؤلفون: Mwangi VI; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil., Netto RLA; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil., de Morais CEP; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil.; Fundação de Medicina Tropical Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil., Silva AS; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil., Silva BM; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil.; Fundação de Medicina Tropical Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil., Lima AB; Programa de Pós-Graduação em Imunologia Básica e Aplicada, Instituto de Ciências Biológicas, Universidade Federal do Amazonas (UFAM), Manaus, Brazil.; Diretoria de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, Brazil., Neves JCF; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil., Borba MGS; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil.; Fundação de Medicina Tropical Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil., Val FFAE; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil.; Fundação de Medicina Tropical Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil., de Almeida ACG; Fundação de Medicina Tropical Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil.; Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás (UFG), Goiânia, Brazil., Costa AG; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil.; Fundação de Medicina Tropical Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil.; Programa de Pós-Graduação em Imunologia Básica e Aplicada, Instituto de Ciências Biológicas, Universidade Federal do Amazonas (UFAM), Manaus, Brazil.; Diretoria de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, Brazil.; Escola de Enfermagem de Manaus, Universidade Federal do Amazonas (UFAM), Manaus, Brazil.; Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM) Universidade do Estado do Amazonas (UEA), Manaus, Brazil., Sampaio VS; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil.; Fundação de Medicina Tropical Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil.; Instituto Todos pela Saúde, São Paulo, São Paulo, Brazil., Gardinassi LG; Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás (UFG), Goiânia, Brazil., de Lacerda MVG; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil.; Fundação de Medicina Tropical Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil.; Instituto Leônidas & Maria Deane/Fundação Oswaldo Cruz (ILMD/Fiocruz Amazônia), Manaus, Brazil., Monteiro WM; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil.; Fundação de Medicina Tropical Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil., de Melo GC; Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, Brazil.; Fundação de Medicina Tropical Heitor Vieira Dourado (FMT-HVD), Manaus, Brazil.; Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM) Universidade do Estado do Amazonas (UEA), Manaus, Brazil.
المصدر: Frontiers in immunology [Front Immunol] 2023 Aug 16; Vol. 14, pp. 1229611. Date of Electronic Publication: 2023 Aug 16 (Print Publication: 2023).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: HMGB1 Protein* , COVID-19*, Humans ; Cytokines ; Interleukin-10 ; Interleukin-17 ; Methylprednisolone/therapeutic use ; Chemokine CXCL10 ; Interleukin-2 ; Interleukin-6 ; Myoglobin ; SARS-CoV-2 ; Interleukin-12
مستخلص: Background: The novel coronavirus disease 2019 (COVID-19) presents with complex pathophysiological effects in various organ systems. Following the COVID-19, there are shifts in biomarker and cytokine equilibrium associated with altered physiological processes arising from viral damage or aggressive immunological response. We hypothesized that high daily dose methylprednisolone improved the injury biomarkers and serum cytokine profiles in COVID-19 patients.
Methods: Injury biomarker and cytokine analysis was performed on 50 SARS-Cov-2 negative controls and 101 hospitalized severe COVID-19 patients: 49 methylprednisolone-treated (MP group) and 52 placebo-treated serum samples. Samples from the treated groups collected on days D1 (pre-treatment) all the groups, D7 (2 days after ending therapy) and D14 were analyzed. Luminex assay quantified the biomarkers HMGB1, FABP3, myoglobin, troponin I and NTproBNP. Immune mediators (CXCL8, CCL2, CXCL9, CXCL10, TNF, IFN-γ, IL-17A, IL-12p70, IL-10, IL-6, IL-4, IL-2, and IL-1β) were quantified using cytometric bead array.
Results: At pretreatment, the two treatment groups were comparable demographically. At pre-treatment (D1), injury biomarkers (HMGB1, TnI, myoglobin and FABP3) were distinctly elevated. At D7, HMGB1 was significantly higher in the MP group (p=0.0448) compared to the placebo group, while HMGB1 in the placebo group diminished significantly by D14 (p=0.0115). Compared to healthy control samples, several immune mediators (IL-17A, IL-6, IL-10, MIG, MCP-1, and IP-10) were considerably elevated at baseline (all p≤0.05). At D7, MIG and IP-10 of the MP-group were significantly lower than in the placebo-group (p=0.0431, p=0.0069, respectively). Longitudinally, IL-2 (MP-group) and IL-17A (placebo-group) had increased significantly by D14. In placebo group, IL-2 and IL-17A continuously increased, as IL-12p70, IL-10 and IP-10 steadily decreased during follow-up. The MP treated group had IL-2, IFN-γ, IL-17A and IL-12p70 progressively increase while IL-1β and IL-10 gradually decreased towards D14. Moderate to strong positive correlations between chemokines and cytokines were observed on D7 and D14.
Conclusion: These findings suggest MP treatment could ameliorate levels of myoglobin and FABP3, but appeared to have no impact on HMGB1, TnI and NTproBNP. In addition, methylprednisolone relieves the COVID-19 induced inflammatory response by diminishing MIG and IP-10 levels. Overall, corticosteroid (methylprednisolone) use in COVID-19 management influences the immunological molecule and injury biomarker profile in COVID-19 patients.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Mwangi, Netto, de Morais, Silva, Silva, Lima, Neves, Borba, Val, de Almeida, Costa, Sampaio, Gardinassi, de Lacerda, Monteiro and de Melo.)
References: Microb Pathog. 2020 Nov;148:104484. (PMID: 32916246)
Heart. 2020 Oct;106(19):1512-1518. (PMID: 32817312)
Hum Genomics. 2020 Sep 11;14(1):30. (PMID: 32917282)
Indian J Pediatr. 2020 Apr;87(4):281-286. (PMID: 32166607)
Postgrad Med J. 2020 Jul;96(1137):387-391. (PMID: 32434874)
Int J Mol Sci. 2022 Feb 16;23(4):. (PMID: 35216286)
Mol Med. 2020 Oct 29;26(1):97. (PMID: 33121429)
N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530)
Expert Rev Anti Infect Ther. 2021 Dec;19(12):1553-1562. (PMID: 34015985)
Circ Res. 2020 May 8;126(10):1443-1455. (PMID: 32252591)
Infect Disord Drug Targets. 2022;22(2):e270821195910. (PMID: 34455971)
J Am Heart Assoc. 2021 Dec 21;10(24):e022913. (PMID: 34889112)
PLoS One. 2020 Apr 29;15(4):e0231687. (PMID: 32348339)
Thorax. 2004 May;59(5):414-20. (PMID: 15115870)
Shock. 2009 Jul;32(1):17-22. (PMID: 19533845)
Mayo Clin Proc. 2011 Oct;86(10):1005-7. (PMID: 21964178)
Ann Clin Biochem. 2002 Jul;39(Pt 4):404-5. (PMID: 12117445)
Eur J Heart Fail. 2021 Mar;23(3):456-464. (PMID: 33421281)
Nat Med. 2020 Aug;26(8):1200-1204. (PMID: 32555424)
J Immunol Methods. 1995 Jan 13;178(1):99-111. (PMID: 7829870)
Science. 2020 Nov 13;370(6518):861-865. (PMID: 33082294)
Front Pediatr. 2021 Mar 30;8:607647. (PMID: 33859967)
Cell Mol Immunol. 2020 Sep;17(9):992-994. (PMID: 32620787)
Cytokine Growth Factor Rev. 2021 Dec;62:54-61. (PMID: 34503914)
Clin Infect Dis. 2020 Jul 28;71(15):762-768. (PMID: 32161940)
Respir Res. 2020 Apr 15;21(1):83. (PMID: 32293449)
Inflammopharmacology. 2022 Jun;30(3):811-820. (PMID: 35471628)
Int Braz J Urol. 2021 May-Jun;47(3):637-646. (PMID: 33621014)
Cells. 2022 Mar 08;11(6):. (PMID: 35326373)
Front Cardiovasc Med. 2021 Aug 12;8:686328. (PMID: 34458331)
Respirology. 2014 Aug;19(6):929-35. (PMID: 24909304)
Cancer Treat Rev. 2018 Feb;63:40-47. (PMID: 29207310)
J Clin Med. 2020 Jul 27;9(8):. (PMID: 32726951)
Ann Intensive Care. 2021 Feb 18;11(1):36. (PMID: 33604873)
Cell. 2016 Nov 3;167(4):1111-1124.e13. (PMID: 27814508)
Nat Commun. 2021 Jul 29;12(1):4677. (PMID: 34326336)
J Coll Physicians Surg Pak. 2018 Jan;28(1):56-60. (PMID: 29290194)
Cardiol Res. 2020 Dec;11(6):398-404. (PMID: 33224386)
Am J Trop Med Hyg. 2021 May 03;105(1):73-80. (PMID: 33939645)
PLoS One. 2013 Jun 14;8(6):e65994. (PMID: 23799067)
Trends Immunol. 2007 Oct;28(10):429-36. (PMID: 17845865)
PLoS One. 2021 May 19;16(5):e0251819. (PMID: 34010310)
Br J Clin Pharmacol. 2022 Jan;88(1):155-165. (PMID: 34087003)
J Cell Mol Med. 2022 May;26(10):3022-3030. (PMID: 35419946)
BMJ. 2020 Mar 26;368:m1091. (PMID: 32217556)
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028. (PMID: 32286245)
Ecancermedicalscience. 2020 Mar 27;14:1022. (PMID: 32256705)
Clin Transl Sci. 2023 Apr;16(4):631-646. (PMID: 36631939)
Mol Cell Biochem. 1992 Oct 21;116(1-2):155-62. (PMID: 1480144)
J Neurotrauma. 2021 Jan 1;38(1):1-43. (PMID: 33115334)
J Int Med Res. 2021 Jul;49(7):3000605211030124. (PMID: 34250826)
J Neurol. 2020 Dec;267(12):3476-3478. (PMID: 32647900)
Heliyon. 2020 Dec 07;6(12):e05672. (PMID: 33313438)
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):183-184. (PMID: 32164084)
Signal Transduct Target Ther. 2020 Jul 25;5(1):128. (PMID: 32712629)
Ann Hematol. 2021 Mar;100(3):675-689. (PMID: 33523290)
Lancet. 2020 Feb 15;395(10223):473-475. (PMID: 32043983)
Clin Infect Dis. 2021 May 4;72(9):e373-e381. (PMID: 32785710)
J Med Virol. 2021 Mar;93(3):1304-1313. (PMID: 33002209)
J Immunol Methods. 2003 Aug;279(1-2):91-100. (PMID: 12969550)
Infection. 2020 Dec;48(6):861-870. (PMID: 32725595)
J Intensive Care. 2020 Jul 10;8:49. (PMID: 32665858)
Front Cardiovasc Med. 2021 Nov 18;8:757799. (PMID: 34869669)
J Clin Med. 2019 Sep 13;8(9):. (PMID: 31540339)
Hematol Transfus Cell Ther. 2020 Apr - Jun;42(2):116-117. (PMID: 32284281)
JAMA Intern Med. 2020 Jul 1;180(7):934-943. (PMID: 32167524)
Front Immunol. 2021 Apr 01;12:622176. (PMID: 33868239)
Clin Pract. 2020 May 28;10(2):1271. (PMID: 32509258)
Am J Transplant. 2002 Jul;2(6):560-7. (PMID: 12118901)
Kardiologiia. 2003;43(5):4-8. (PMID: 12891232)
Int J Lab Hematol. 2021 Apr;43(2):160-168. (PMID: 33264492)
Ann Neurol. 2021 Mar;89(3):610-616. (PMID: 33377539)
J Neurol. 2021 Dec;268(12):4436-4442. (PMID: 33973106)
Front Med (Lausanne). 2021 Nov 30;8:758405. (PMID: 34917633)
Neuroimmunomodulation. 2014;21(6):322-30. (PMID: 24642726)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
Clin Biochem. 2001 Jun;34(4):257-63. (PMID: 11440724)
Int J Infect Dis. 2021 Apr;105:551-559. (PMID: 33711519)
Expert Rev Respir Med. 2022 Jan;16(1):79-89. (PMID: 34541972)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Cytokine. 2018 Oct;110:374-380. (PMID: 29656958)
CMAJ. 2020 Jul 6;192(27):E756-E767. (PMID: 32409522)
Crit Rev Clin Lab Sci. 2020 Sep;57(6):389-399. (PMID: 32503382)
J Med Chem. 2018 Jun 28;61(12):5093-5107. (PMID: 29268019)
Orthop Nurs. 2019 Sep/Oct;38(5):336-339. (PMID: 31568125)
Cell Death Differ. 2012 Jan;19(1):96-106. (PMID: 22033335)
Clin Exp Immunol. 2004 Apr;136(1):95-103. (PMID: 15030519)
Clin Infect Dis. 2021 Apr 8;72(7):1297-1298. (PMID: 32588877)
J Allergy Clin Immunol. 2020 Jul;146(1):89-100. (PMID: 32407836)
Clin Exp Med. 2020 Nov;20(4):493-506. (PMID: 32720223)
Leukemia. 2020 Jun;34(6):1503-1511. (PMID: 32372026)
J Autoimmun. 2021 Mar;118:102598. (PMID: 33524876)
فهرسة مساهمة: Keywords: SARS-CoV-2; biomarkers; cytokine; immune mediators; injury; methylprednisolone
المشرفين على المادة: 0 (Cytokines)
130068-27-8 (Interleukin-10)
0 (HMGB1 Protein)
0 (Interleukin-17)
X4W7ZR7023 (Methylprednisolone)
0 (Chemokine CXCL10)
0 (Interleukin-2)
0 (Interleukin-6)
0 (Myoglobin)
187348-17-0 (Interleukin-12)
تواريخ الأحداث: Date Created: 20230904 Date Completed: 20230905 Latest Revision: 20230915
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC10468998
DOI: 10.3389/fimmu.2023.1229611
PMID: 37662953
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2023.1229611